Vicore Pharma (NASDAQ:VCRE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Vicore Pharma (NASDAQ:VCRE) to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other research firms also recently commented on VCRE. Jefferies Financial Group assumed coverage on shares of Vicore Pharma in a report on Friday, October 9th. They set a “buy” rating and a $25.00 price objective for the company. Weiss Ratings assumed coverage on Vicore Pharma in a report on Thursday, October 8th. They issued a “sell (e-)” rating on the stock. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $25.00.

Vicore Pharma Stock Up 0.2%

Shares of NASDAQ:VCRE opened at $9.40 on Friday. Vicore Pharma has a fifty-two week low of $7.88 and a fifty-two week high of $17.80.

Vicore Pharma (NASDAQ:VCRE) last posted its earnings results on Friday, August 21st. The company reported ($0.05) earnings per share for the quarter. The company had revenue of $0.23 million for the quarter.

About Vicore Pharma

Vicore Pharma is a Swedish biopharmaceutical company focused on developing medicines for severe respiratory and pulmonary diseases. The company’s research is centered on treatments intended to address the underlying disease processes associated with conditions such as idiopathic pulmonary fibrosis and other forms of progressive lung fibrosis.

Vicore’s lead investigational program is buloxibutid, formerly known as C21, an orally administered small-molecule agonist of the angiotensin II type 2 receptor.